ID | 116819 |
著者 |
Iwatsuki, N
Sakamoto Hospital
Okada, M
Sakamoto Hospital
|
キーワード | Oral hypoglycemic agents (OHAs)
Imeglimin
type 2 diabetes mellitus (T2DM)
Glucose-stimulated insulin secretion (GSIS)
Treatment-emergent adverse events (TEAEs)
American Diabetes Association (ADA)
|
資料タイプ |
学術雑誌論文
|
抄録 | Latest Standards of Medical Care in Diabetes was presented in January 2022. Among oral hypoglycemic agents (OHAs), imeglimin has been topic for a novel agent for type 2 diabetes mellitus (T2DM). Pharmacologically, imeglimin is a cyclic molecule including triazine ring. It has both pharmacological mechanism of increased insulin action and elevation of glucose-stimulated insulin secretion (GSIS). Clinically, it showed HbA1c reduction for 0.46% by monotherapy and 0.56-0.92% by combined therapy with other OHAs. From compared administration of 500mg, 1000mg and 1500mg, 1000mg twice doses would be adequate. No remarkable treatment-emergent adverse events (TEAEs) were found for treatment of imeglimin.
|
掲載誌名 |
SunText Review of Pharmaceutical Sciences
|
ISSN | 27665232
|
出版者 | SunText Reviews
|
巻 | 3
|
号 | 1
|
開始ページ | 113
|
発行日 | 2022-01-23
|
権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|